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John E. Levine,1 Brent Logan,2 Juan Wu,3 Amin M. Alousi,4 Vincent Ho,5
Javier Bolan˜os-Meade,6 Daniel Weisdorf,7 on behalf of the Blood and Marrow
Transplant Clinical Trials NetworkAcute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the
major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical
trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT
survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to re-
liably categorize patients at high risk for death or to promptly identify those whomight benefit from alternate
treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who
were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of
GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was
to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival.
We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for
NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response
(complete or partial response) best categorized patients by NRM and survival at 9 months from start of
aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment
approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.
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Allogeneic hematopoietic cell transplant (HCT)
is used as a curative therapy for a large number of
malignant and nonmalignant hematologic diseases.
Graft-versus-host disease (GVHD) is the major reasonDepartments of Pediatrics and InternalMedicine,Univer-
f Michigan, Ann Arbor, Michigan; 2Center for Interna-
Blood and Marrow Transplant Research (CIBMTR),
al College of Wisconsin, Milwaukee, Wisconsin; 3The
ES Corporation, Rockville, Maryland; 4Department of
Cell Transplantation and Cellular Therapy, University
xas M.D. Anderson Cancer Center, Houston, Texas;
rtment of Medical Oncology/Hematologic Malignancies,
Farber Cancer Institute, Boston,Massachusetts; 6Depart-
of Oncology, The Johns Hopkins University, Baltimore,
and; and 7Blood and Marrow Transplant Program,
rsity of Minnesota, Minneapolis, Minnesota.
isclosure: See Acknowledgments on page 1699.
dence and reprint requests: John E. Levine, MD, MS,
tments of Pediatrics and Internal Medicine, University of
gan, 5303 Cancer Center, 1500 E. Medical Center Drive,
rbor, MI 48109-5941 (e-mail: jelevine@umich.edu).
pril 26, 2010; accepted May 27, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.05.019fornonrelapsemortality (NRM), and is stagedandgraded
according to severityof symptoms in3 targetorgans (skin,
liver, andgastrointestinal tract) [1].EffectiveGVHDpre-
vention remains an area of active clinical research, but at
present, most patients are administered prophylactic
agents that interfere with T-lymphocyte numbers or
function [2-4]. Neverthe-less, large numbers of patients
develop acute GVHD (aGVHD) requiring treatment.
Patients whose GVHD does not respond to treatment,
generally high doses of corticosteroids, experience
particularly high rates of mortality [5,6], and new
treatments for steroid-refractory patients are needed [7].
However, it is not clear at present how quickly response
to GVHD treatment needs to be established to reliably
categorize patients at high risk for death or to promptly
identify those who might benefit from alternate treat-
ment. Therefore, we analyzed time to response from
onset of aGVHD treatment in 180 patients who were
enrolled on a national, randomized, phase II aGVHD
treatment clinical trial whose initial treatment of
GVHDconsisted of high-dose steroids plus a second im-
munosuppressive agent [8]. The aim of this secondary
analysis was to determine whether time to GVHD
treatment response predicts patient outcomes, especially
survival.1693
1694 Biol Blood Marrow Transplant 16:1693-1699, 2010J. E. Levine et al.METHODS
The patients, their GVHD characteristics, and
GVHD treatment for this study have all been previously
described [8]. Briefly, patients 6 yearsof age or olderwho
had undergone an allogeneic HCT in which bone mar-
row (BM), peripheral blood (PB), or umbilical cord
blood (UCB) grafts were used and had newly diagnosed
aGVHDrequiring systemic therapywere eligible for in-
clusion. Biopsy confirmation of GVHD was encour-
aged, but not required. Patients could not have
received previous systemic immunosuppressive therapy
for the treatment of GVHD, except for a maximum 48
hours of previous steroid therapy ($1 mg/kg per day
methylprednisolone). Patients with uncontrolled infec-
tions, absolute neutrophil counts (ANCs)\500 mL, or
creatinine clearances of\30 mL/min/1.73 m2 were ex-
cluded. Also ineligible were patients who received a do-
nor lymphocyte infusion,unless aspartof their originally
planned transplant therapy (andnot forpersistent/recur-
rent disease), or patients whose clinical condition made
deviation from the protocol-mandated therapy likely,
including the suggested steroid taper schedule. The
protocol and informed consents were approved by the
Protocol ReviewCommittee and Data and SafetyMon-
itoring Board of the National Heart, Lung, and Blood
Institute (NHLBI) and the review boards of all partici-
pating institutions. All patients or their parents signed
institutionally approved informed consents.Study Design
The study was a multicenter, randomized, 4-arm
phase II trial conductedby theBlood andMarrowTrans-
plant Clinical Trials Network (BMT CTN). The trial
was designed to evaluate the safety and efficacy of 4
agents, each in combination with corticosteroids. Eligi-
ble patientswhohadnot receivedmycophenolatemofetil
(MMF, Cellcept) for GVHDprophylaxis within 7 days
of enrollment were randomized to 1 of the 4 treatment
arms consisting ofMMF, etanercept, denileukin diftitox,
or pentostatin, each in combination withmethylprednis-
olone 2 mg/kg per day intravenously (or prednisone
2.5 mg/kg per day orally) in a 2:1:1:1 ratio, respectively.
Patients who had receivedMMF forGVHDprophylaxis
within 7 days of onset ofGVHDwere not randomized to
MMF, but were randomized to the 3 non-MMF arms in
equal proportions. This randomization scheme balanced
all 4 arms such that approximately equal numbers of
patients received each of the 4 study drugs. The primary
endpoint for the study was the proportion of patients in
complete response (all GVHD target organs staged as
zero) on day 28 from start of study treatment.Treatment of GVHD
Study treatment began within 48 hours of random-
ization and included corticosteroids plus 1 of the 4study drugs. Patients received methylprednisolone
2 mg/kg per day intravenously (or prednisone
2.5 mg/kg per day orally) divided in 2 to 3 daily doses
for no less than 7 days. Steroids could then be tapered
as tolerated to no less than methylprednisolone
0.6 mg/kg per day (prednisone 0.75 mg/kg per day)
at day 28. A suggested steroid taper schedule was pro-
vided; however, adherence was optional apart from
days 7 and 28 stipulations. Patients whose GVHD
was progressing after 7 days, had no response (NR)
by 14 days, or were not in a complete response (CR)
at day 28 could receive secondary therapy, but were
still followed for study endpoints. Patients who
achieved a day 28 CR and had a subsequent flare of
aGVHD could receive the same or alternative agents
at the treating physician’s discretion or, alternatively,
receive a temporary increase in the dose of steroids.
Patients were maintained on therapeutic levels of
calcineurin inhibitors and received standard support-
ive care, including transfusions and antiinfective
prophylaxis per institutional practices.
GVHD Scoring and Response Assessment
GVHD was scored by the consensus criteria [1]
and reported weekly to the BMT CTN Data and
Coordinating Center along with biopsy results, differ-
ential diagnosis, and GVHD therapy through week 8
and at 3, 4, 6, and 9 months after study enrollment.
CRwas defined as resolution of all signs and symptoms
of GVHD in all organs without intervening salvage
therapies. A partial response (PR) was defined as an im-
provement of 1 stage in 1 or more organs without pro-
gression in any organ. Mixed response was considered
an improvement in at least 1 organ with progression or
newly developed GVHD in another organ(s). NR was
defined as absence of improvement or deterioration
within 14 days of therapy initiation. Progression was
defined as worsening by 1 or more stages without
improvement in any involved organ. In patients who
received secondary therapy, subsequent GVHD evalu-
ations were classified as nonresponding. Toxicity,
infections, and GVHD flares (increase in symptoms
or therapy for GVHD after an initial response) were
recorded through day 90. GVHD-free survival was
calculated by the proportion of patients in each study
arm who were alive at day 56, achieved a CR, and
who had not experienced a GVHD-flare, chronic
GVHD (cGVHD), or need for additional therapy. A
study endpoint committee, blinded to study drug
assignment, reviewed all response and endpoint data
prior to analysis.
Statistical Analysis
Baseline pretransplant factors and GVHD charac-
teristics at study entry were described and their associ-
ation with response outcomes were assessed using
Biol Blood Marrow Transplant 16:1693-1699, 2010 1695GVHD Treatment: Predictors of Survivalchi-square tests or Fisher’s exact test as appropriate.
Survival probabilities at 180 days and 270 days after
randomization were estimated according to response
status at days 14, 28, or 56 using the Kaplan-Meier
estimate restricted to patients alive at each response
assessment time. Probabilities of NRMwere estimated
using the cumulative incidence technique. Log trans-
formations were used to construct confidence intervals
for the survival probabilities and cumulative incidence
probabilities. Cox proportional hazards regression
models with backward selection were used to build
prognostic factor models for mortality and NRM. A
P-value of#.05 was considered significant for remain-
ing in the model. The proportionality assumption for
Cox regression was tested by adding a time-
dependent covariate for each risk factor and each
outcome. Tests indicated that all variables met the
proportional-hazards assumption. Results were ex-
pressed as relative risks (RR) of occurrence of the
event. The following variables were considered inmul-
tivariate analyses: age at transplant, donor type, condi-
tioning intensity, source of stem cells, time to onset of
GVHD, grade of GVHD at study entry, and multior-
gan GVHD involvement. In addition, response assess-
ment at days 14, 28, or 56, as well as the occurrence of
flare after CR were incorporated into the proportional
hazards model using time-dependent covariates. Sen-
sitivity and specificity calculations were used to assess
the accuracy of GVHD response at each timepoint as
a surrogate outcome for 180-day mortality.Table 1. Baseline Characteristics (Pretransplant and at GVHD On
Baseline Characteristic Patient Number CR, % (n 5
Donor type
Related 84 48%
Unrelated 94 44%
Conditioning regimen
Myeloablative 116 45%
Reduced intensity 62 47%
Stem cell source
Peripheral blood 109 44%
Bone marrow 44 48%
Cord blood 25 48%
Age group
<35 y 46 48%
35-54 y 73 38%
$55 y 61 51%
Time to onset of aGVHD
<30 days 89 39%
$30 91 51%
GVHD grade at treatment onset
0-I 22 55%
II 102 46%
III-IV 56 39%
Multiorgan involvement
No 114 46%
Yes 66 44%
GVHD indicates graft-versus-host disease; aGVHD, acute graft-versus-host
response rate (and is complete response [CR] plus PR [partial response]); y, y
P-value is for comparison of CR, PR, and no response (NR) with risk factors, Tw
regimen, and stem cell source.RESULTS
Effect of Baseline Characteristics on Response
to Treatment
Response rates by day 28 based on baseline charac-
teristics (pretransplant and at study enrollment) are
shown in Table 1. Donor type, conditioning intensity,
stem cell source, and age did not influence the likeli-
hood of response to initial GVHD treatment at day
28 or at the other time points analyzed (days 14 and
56). A higher proportion of patients whose GVHD
developed more than 30 days from the transplant
achieved a CR within 28 days of initiation of GVHD
treatment (69% versus 55%), but this difference was
not statistically significant (P 5 .09).Effect of aGVHD Characteristics at Study Entry
on Outcomes
Not surprisingly, GVHD grade at initiation of
treatment correlatedwith response to treatment. Specif-
ically, patients with grade III/IV aGVHDat study entry
were less likely tohave responded to treatment byday28
compared topatientswith less severe aGVHD(P5 .05).
BecauseGVHDgrade represents a composite score that
includes staging of each target organ, we investigated
whether target organ involvement and severity (eg, GI
versus skin GVHD) predicted response to treatment.
Patients with grade I GVHD have only skin involve-
ment, whereas visceral involvement is a requirementset) by day 28 Response
81) PR, % (n 5 30) ORR, % (n 5 111) P Value
.85
15% 63%
18% 62%
.66
16% 61%
18% 65%
.2
14% 58%
18% 66%
28% 76%
.84
15% 63%
21% 59%
13% 64%
.09
16% 55%
18% 69%
.05
4% 59%
23% 69%
11% 50%
.53
14% 60%
21% 65%
disease; CR, complete response; PR, partial response; ORR, overall
ears.
o subjects are missing baseline in formation of donor type, conditioning
Table 2. Day 28 Response by GVHD Grade and Organ at
Treatment Onset
GVHD
Grade/Organ Number
CR, %
(n 5 81)
PR, %
(n 5 30)
ORR, %
(n 5 111) P Value
Grade 0/I 22 55% 4% 59% NA
Grade II 102 46% 23% 69% .94
Skin alone 59 46% 24% 70%
Gut/Liver +/2 skin 43 47% 21% 67%
Grade III/IV 56 39% 11% 50% NA
CR indicates complete response; PR, partial response; ORR, overall
response rate; GVHD, graft versus-host-disease; N/A, not applicable.
Table 3. Cox Regression Model for Baseline Characteristics
on OS
Variable
OS
N RR P Value
GVHD grade at onset
0-II 123 1.00
III-IV 55 1.92 (1.20-3.06) .01
Donor type
Related 84 1.00
Unrelated 94 1.80 (1.11-2.90) .02
Stem cell source
Peripheral Blood 109 1.00
Bone Marrow 44 0.63 (0.37-1.07) .09
Cord Blood 25 0.38 (0.18-0.81) .01
OS indicates overall survival; RR, relative risk; GVHD, graft-versus-host
disease.
1696 Biol Blood Marrow Transplant 16:1693-1699, 2010J. E. Levine et al.for grade III GVHD. For grade II GVHD, we tested
whether patients with skin GVHD alone were likely to
have different response rates than patients withmultior-
gan GVHD. As shown in Table 2, the day 28 overall
response rate (ORR) for skin GVHD alone (70%) was
not different than the ORR for multiorgan GVHD
(67%, P5 .94). There were too few patients with grade
III/IV disease to permit valid statistical comparisons
based upon organ staging, but the frequencies of
response are as shown.
Given that at GVHD is the major cause of NRM,
we then performed a multivariate analysis using a Cox
regression model to determine which characteristics
present at the time of study entry had a significant
impact on NRM and overall survival (OS) over the
9-month follow-up period. Only GVHD grade at
study entry had a significant impact on NRM. The
relative risk of NRM was 1.72 (95% confidence inter-
val [CI] 1.13-2.59) for patients with grade III-IV
GVHD at study entry, compared to patients with
GVHD grade II or lower. As shown in Table 3, using
a backward elimination regression method to identify
independent factors affecting OS, GVHD grade at
study entry, donor type, and stem cell source were
found to significantly affect OS. After accounting for
GVHD grade, organ involvement had no statistically
significant impact either as a main effect or as an inter-
action. As noted earlier, this is likely because GVHD
organ involvement is a major factor in determining
GVHD grade.Effect of Time to Response to Treatment on
Outcomes
GVHD responses for survivors at each time point
were categorized according to whether patients were
in CR or PR at day 14, day 28, and day 56. We then
determined which of these categories correlated best
with survival at 6 and 9 months following initiation of
GVHD treatment. Survival significantly varied accord-
ing to CR or PR status at day 14. However, survival was
similar for both CR and PR at day 28 and day 56. The
poorest 6-month survival was seen in those patients
with NR at day 28 (Figure 1D–F and Table 4). NRM
followed a similar pattern. NRM was significantlyimproved based on CR versus PR at day 14, but, at
both day 28 and day 56, patients who achieved either
CR or PR experienced similar NRM (Figure 1A-C).
We also determined the sensitivity and specificity
for responses at day 14, day 28, and day 56 to predict
survival. Sensitivitywas defined as the proportion of pa-
tients who did not respond to treatment among those
who died by 6 months. As shown in Table 5, patients
who did not achieve CR by day 14 accounted for the
highest proportion of deaths (83%) within 6 months
of initiating GVHD treatment. Specificity was defined
as the proportion of patients who responded to treat-
ment among those who were alive at 6 months. CR 1
PR at every time point was a better predictor for
6-month survival than CR alone, particularly showing
greater specificity for predicting survival. Not surpris-
ingly, specificity improves when likelihood of survival
at 6 months is analyzed at time points closer to 6
months.
To further interpret these early response findings
as predictors of later outcome, we analyzed the effect
of response to treatment onNRM andOS after adjust-
ing for baseline characteristics. As shown in Table 6,
patients who did not achieve PR or CR at each time
point were at significantly greater risk for NRM and
death by 9 months. Patients with either CR or PR at
day 28 had almost identical long-term outcomes. Alto-
gether, these analyses indicate that either CR or PR
(versus NR) to GVHD treatment at day 28 is the
best surrogate for later outcomes, such as NRM and
survival.
We also considered whether a GVHDflare (return
of GVHD symptoms in patients who had previously
achieved aCR) influenced these findings. In amultivar-
iate analysis, a flare after an earlier CR did not increase
the risk of NRM (RR 5 1.18 [95% CI 0.66-2.13],
P5 .58). Finally, we performed a multivariate analysis
to determine whether response assessed at days 14, 28,
or 56 correlated with risk of developing cGVHD.
There was no significant effect of response status on
cGVHD, using the Cox proportional hazards model.
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Figure 1. Cumulative incidence of nonrelapse mortality (NRM*) and Kaplan-Meier curves of overall survival (OS) by response status. *Overall P-value
computed using Gray’s test: (A) NRM by day 14 response; (B) NRM by day 28 response; (C) NRM by day 56 response; (D) OS by day 14 response; (E) OS
by day 28 response; and (F) OS by day 56 response.
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One challenge in GVHD treatment is determining
the key predictive factors for outcomes; particularly
early findings that predict later outcomes. In this study
of 180 patients newly diagnosed with GVHD who
were prospectively treated with systemic steroids plusTable 4. Overall Survival Among Patients Alive and Evaluable for
Time Points Response Status
Number Alive and
Evaluable for Response 6-Month Su
Day 14 177
CR 60 80.0% (67
PR 46 69.6% (54
NR 71 40.8% (29
Day 28 167
CR 81 77.7% (67
PR 30 80.0% (60
NR 56 39.3% (26
Day 56 147
CR 105 81.9% (73
PR 18 66.7% (40
NR 24 45.8% (25
CI indicates confidence interval; CR, complete response; PR, partial response
*P-value computed using log-rank test.a second agent, treatment response at multiple time
points were highly predictive of NRM and survival,
even after adjustment for pretransplant characteristics.
As previously reported, the study was not designed to
test for statistically significant differences in response
rates or long-term outcomes between the 4 different
agents added to high-dose systemic steroid therapyResponse at Days 14, 28, and 56
rvival (95% CI) 9-Month Survival (95% CI) P-Value* by 9 Months
.4%, 88.1%) 77.9% (65.0%, 86.6%) <.0001
.1%, 80.7%) 55.4% (39.6%, 68.6%)
.4%, 51.9%) 30.2% (19.9%, 41.2%)
.0%, 85.3%) 67.4% (55.9%, 76.5%) <.0001
.8%, 90.5%) 68.0% (47.2%, 82.1%)
.6%, 51.7%) 33.8% (21.8%, 46.1%)
.1%, 88.0%) 71.2% (61.2%, 79.1%) .0001
.4%, 83.4%) 61.1% (35.3%, 79.2%)
.6%, 64.0%) 33.3% (15.9%, 51.9%)
; NR, no response.
Table 5. Sensitivity and Specificity Statistics for Various Re-
sponseOutcomes atDays 14, 28, and 56with Survival Status at
6 Months
Time
Points
Response
Status
Dead at
6 Months
Alive at
6 Months Sensitivity Specificity
Day 14 Not CR 58 61 83% 44%
CR 12 47
Day 28 Not CR 52 46 74% 57%
CR 18 62
Day 56 Not CR 51 23 73% 79%
CR 19 85
Day 14 Not CR + PR 44 29 63% 73%
CR + PR 26 79
Day 28 Not CR + PR 46 22 66% 80%
CR + PR 24 86
Day 56 Not CR + PR 45 11 64% 90%
CR + PR 25 97
CR indicates complete response; PR, partial response.
1698 Biol Blood Marrow Transplant 16:1693-1699, 2010J. E. Levine et al.[8]; therefore, the distinction between the second agents
was not further pursued as a variable in this analysis.
The relationship between GVHD grade and long-
term outcomes is complex and imperfect [9]. It is well
established that as GVHD severity increases, mortality
increases, even though the correlation is not strictly
linear [6]. Other factors that predict outcome have
been less well characterized. Time to GVHD response
might be an important predictor of outcome, but the
incorporation of this variable in clinical trial design
and interpretation requires validation [10]. The 3 re-
sponse timepoints tested all showed utility as surrogate
markers for later outcomes. In this analysis, we identi-
fied overall response rate (CR 1 PR) at day 28 being
most predictive of both 9-month NRM and survival.
In addition, patients who failed to achieve any response
by day 14 experienced high mortality rates. Given the
steep decrease in survival for patients with NR by day
14, the day 14 response endpoint may have value for
determining which patients are unlikely to realize
benefit from agents under study and may require
additional intervention.
Interestingly, pretransplant characteristics that
categorize patients for risk of developing GVHD,
such as donor type (related versus unrelated), age,Table 6. Cox Regression Model on NRM and OS Including Effect
Baseline Characteristics from Table 3
Time
Points Response Status N RR
Day 14 CR 60 1.00
PR 46 2.09 (1.12-3.8
NR 71 4.04 (2.32-7.0
Day 28 CR 81 1.00
PR 30 0.99 (0.52-1.8
NR 56 2.32 (1.44-3.7
Day 56 CR 105 1.00
PR 18 1.16 (0.54-2.5
NR 24 1.65 (1.09-2.5
NRM indicates nonrelapse mortality; OS, overall survival; RR, relative risk; CRand conditioning intensity did not predict for response
to GVHD treatment. Identification of predictors for
GVHD responsiveness (or lack thereof) will be impor-
tant for future clinical trials. Recent GVHDbiomarker
studies provide hope that advances along these lines
may be forthcoming [11-13].
These survival analyses, together with the sensitiv-
ity and specificity calculations, highlight that the prob-
ability of long-term survival depends only in part on
response to GVHD treatment. Many patients die
despite achieving GVHD response, often because of
opportunistic infections [14,15] and/or cGVHD
[16,17]. Nonetheless, the overall CR plus PR rate at
day 28 to GVHD treatment appears to function well
as a surrogate endpoint for clinical benefit, namely,
long-term survival. Importantly, patients with active,
but responding GVHD (PR) by day 28 contribute to
long-term survival rates. Many of these patients even-
tually achieve CR, highlighting the importance of re-
sponding, rather than CR, by day 28.
A similar analysis of a large cohort of patients
(n 5 864) was recently reported from the University
of Minnesota. The Minnesota study population differs
from the BMT CTN study population in several rele-
vant ways. These differences include a younger popu-
lation all treated at a single center over a 17-year time
period with a disproportionate representation of unre-
lated cord blood as a stem cell source. Therefore, it is
reassuring that the Minnesota analysis also found that
the day 28 response to GVHD therapy correlated best
with long-term outcomes such as 2-year NRM [18].
This analysis, which is derived from a prospective
multicenter trial of initial aGVHD treatment, is
strengthened by the fact that GVHD grading was
done prospectively and GVHD scores and responses
were confirmed by an independent blinded GVHD
grading panel. However, its conclusions may be lim-
ited by the modest sample size and the smaller num-
bers of patients with severe aGVHD. It should be
noted that the response rates on this study were higher
than those historically reported with steroids alone [5].
Although these results are concordant with the largeof Response Assessment at Days 14, 28, and 56, Adjusted for
NRM OS
P-value RR P-value
1.00
8) .02 2.00 (1.03-3.90) .04
2) <.001 4.36 (2.42-7.83) <.001
9) .98 0.96 (0.48-1.94) .91
3) <.001 2.79 ( 1.71-4.55) <.001
1.00
1) .698 1.31 (0.60-2.85) .50
0) .004 4.27 (2.28-7.98) <.001
, complete response; PR, partial response; NR, no response.
Biol Blood Marrow Transplant 16:1693-1699, 2010 1699GVHD Treatment: Predictors of Survivalsingle center results recently reported [18], applicabil-
ity of findings in this analysis to patients treated with
steroids alone, second-line therapy, or to cohorts
with more severe aGVHD, will need further testing.ACKNOWLEDGMENTS
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